Fernanda N. C. Haum
Research Subjects
Fernanda N. C. Haum has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Allan Andresson Lima Pereira
Department of Gastrointestinal Medical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
1 shared publication - Daniel M. Girardi
Hosp Sirio Libanes, Dept Med Oncol, Setor Grandes Areas 613-614 Conjunto & Lote 95-Asa, BR-70200730 Brasilia, Brazil
1 shared publication - Gabriel Clemente Brito Pereira
Hospital de Base do Distrito Federal—Universidade de Brasilia, Brasilia, Brazil
1 shared publication - Lara P. Sousa
Escola Superior de Ciências em Saúde, SMHN Conjunto A Bloco 01 Edifício Fepecs-Asa Norte, Brasília 70710-907, Brazil
1 shared publication - Thiago A. Miranda
Escola Superior de Ciências em Saúde, SMHN Conjunto A Bloco 01 Edifício Fepecs-Asa Norte, Brasília 70710-907, Brazil
1 shared publication
Latest Publications
- Open Access
Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
Hepatocellular carcinoma often develops in the context of chronic liver disease. It is the sixth most frequently diagnosed cancer and the third most common cause of cancer-related mortality worldwide. Although the mainstay of therapy is surgical resection, most patients are not eligible because of liver dysfunction or tumor extent. Sorafenib was the first tyrosine kinase inhibitor that improved the overall survival of patients who failed to respond to local therapies or had advanced disease, and for many years, it was the only treatment approved for the first-line setting. However, in recent years, trials have demonstrated an improvement in survival with treatments based on immunotherapy and new targeting agents, thereby extending the treatment options. A phase III trial showed that a combination of immunotherapy and targeted therapy, including atezolizumab plus bevacizumab, improved survival in the first-line setting, and is now considered the new standard of care. Other agents and combinations are being tested, including the combination of nivolumab plus ipilimumab and tremelimumab plus durvalumab, and they reportedly have clinical benefits. The aim of this manuscript is to review the latest approved therapeutic options in first- and second-line settings for advanced HCC and discuss future perspectives.
Open AccessSystemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
Hepatocellular carcinoma often develops in the context of chronic liver disease. It is the sixth most frequently diagnosed cancer and the third most common cause of cancer-related mortality worldwide. Although the mainstay of therapy is surgical resection, most patients are not eligible because of liver dysfunction or tumor extent. Sorafenib was the first tyrosine kinase inhibitor that improved the overall survival of patients who failed to respond to local therapies or had advanced disease, and for many years, it was the only treatment approved for the first-line setting. However, in recent years, trials have demonstrated an improvement in survival with treatments based on immunotherapy and new targeting agents, thereby extending the treatment options. A phase III trial showed that a combination of immunotherapy and targeted therapy, including atezolizumab plus bevacizumab, improved survival in the first-line setting, and is now considered the new standard of care. Other agents and combinations are being tested, including the combination of nivolumab plus ipilimumab and tremelimumab plus durvalumab, and they reportedly have clinical benefits. The aim of this manuscript is to review the latest approved therapeutic options in first- and second-line settings for advanced HCC and discuss future perspectives.